Small cap wrap: Purepoint Uranium, Custom Health, Standard Uranium, Blockmate
Purepoint Uranium approved a 2027 exploration plan for its Dorado project. Custom Health reported 220% revenue growth to US$14.4M. Standard Uranium confirmed geology at its Rocas project. Blockmate Ventures ordered its first NVIDIA B200 compute node. 374Water saw 83% revenue increase. Allergy Therapeutics plans to delist from AIM. Pantheon Resources raised £7.5M. IXICO developed an AI tool for Alzheimer's drug safety checks.
How this was made
The 30-second read
Why it matters
The most tradable signals are the quantified Q3 revenue/gross profit jump for Custom Health, the quantified revenue and cash-burn improvement for 374Water, and the broker forecast/target lift for Ceres Power. Several other names have catalysts that are concrete but still execution-dependent (drilling, hardware installation, AI tool development).
Market read
Traders can use the quantified operating updates and broker forecast changes for near-term positioning, while treating drilling and product/hardware milestones as medium-term optionality.
What to watch
For the AIM delisting and the equity raise, liquidity and dilution mechanics can dominate fundamentals; traders should watch trading halt/stop dates and share issuance details.
Background
This is a multi-name small-cap wrap covering exploration approvals, quarterly results, broker target changes, capital raises, listing changes, and product/technology updates.
Ticker impact
374Water reported nine-month revenue up 83% to US$3.47 million and a sharp reduction in cash used in operations as AirSCWO deployments advance.
Likely positive reaction as investors re-rate the company on accelerating commercial traction and better operating cash efficiency.
The article provides multiple quantified operating metrics (revenue, gross profit, gross margin, and cash used reduction) tied to commercial deployment progress.
Market effects
Uranium exploration updates and AI/healthcare commercialization signals reinforce risk-on interest in small-cap resource and healthcare tech names.
Primarily UK/Canada-listed small caps, with potential spillover into broader AIM and TSX-V sentiment.
Limited direct macro linkage; indirect relevance through AI compute supply chain and healthcare imaging innovation narratives.
Counterpoint
Several items are early-stage (exploration plans, first hardware node, AI tool development) and may not translate into near-term revenue, so price moves could fade quickly.
Key entities
- companyPurepoint Uranium Group Inc
Dorado project JV approved a 2027 exploration plan with 14 diamond drill holes totaling 7,700 metres.
- companyCustom Health Holdings Inc
Q3 revenue rose 220% to US$14.4 million on first full quarter contribution from InnovativeRx.
- companyCeres Power Holdings PLC
UBS raised its target to 1,000p and increased 2027 earnings forecasts by 10% after a new European manufacturing agreement.
- companyStandard Uranium Ltd
Rocas project drilling confirmed basement-hosted uranium system geology and reported rare earth grades up to 0.99%.
- companyBlockmate Ventures Inc
Ordered its first NVIDIA B200 compute node and selected a US data centre for Q1 2027 installation.

